A Phase 1 Study of BGB-B3227 Alone and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514216-27-00

Acronym

BGB-3227-101

Enrollment

Registered

2024-12-11

Start date

2025-01-17

Completion date

Unknown

Last updated

2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026